Driven by innovative products, supported by a CDMO platform

Qingdao Lujian Health Technology is committed to a dual-engine growth strategy that advances in parallel through innovative product development and CDMO platform empowerment. With a strong focus on the high-end medical devices, the company has built an integrated business model centered on product portfolio development and CDMO platform services.

On the product side, the company targets innovative medical devices with clear clinical value, high technical barriers, and strong market potential. By continuously promoting product introduction, R&D transformation, regulatory registration, and commercial deployment, Lujian is accelerating the development and market entry of its core product pipeline.

On the platform side, backed by a CDMO platform aligned with international quality and compliance standards, the company delivers end-to-end solutions for research institutions, innovation teams, medical institutions, and medical device enterprises. Its services span the entire development cycle, including proof of concept, process development, verification and validation, regulatory submission, and scalable manufacturing.

Through this dual-engine approach, Lujian Technology not only continues to deliver competitive innovative products, but also empowers both domestic and international medical device projects to accelerate their transformation from the laboratory to clinical application, and from concept to commercialization. This creates a synergistic ecosystem in which project transformation drives platform growth, while platform capabilities further strengthen product innovation.